Identification of Risk Factors for Gliptin-associated Bullous Pemphigoid among Diabetic Patients
DOI:
https://doi.org/10.2340/actadv.v104.26663Keywords:
autoimmune blistering disease, bullous pemphigoid, bullous drug reaction, drug reaction, dipeptidyl peptidase 4 inhibitor, gliptinAbstract
Drug-associated bullous pemphigoid has been shown to follow long-term gliptin (dipeptidyl-peptidase 4 inhibitors) intake. This study aimed at identifying risk factors for gliptin-associated bullous pemphigoid among patients with type 2 diabetes. A retrospective study was conducted in a tertiary centre among diabetic patients exposed to gliptins between the years 2008–2021. Data including demographics, comorbidities, medications, and laboratory results were collected using the MDClone platform. Seventy-six patients with type 2 diabetes treated with dipeptidyl-peptidase 4 inhibitors who subsequently developed bullous pemphigoid were compared with a cohort of 8,060 diabetic patients exposed to dipeptidyl-peptidase 4 inhibitors who did not develop bullous pemphigoid. Based on a multivariable analysis adjusted for age and other covariates, Alzheimer’s disease and other dementias were significantly more prevalent in patients with bullous pemphigoid (p = 0.0013). Concomitant use of either thiazide or loop diuretics and gliptin therapy was associated with drug-associated bullous pemphigoid (p < 0.0001 for both). While compared with sitagliptin, exposure to linagliptin and vildagliptin were associated with bullous pemphigoid with an odds ratio of 5.68 and 6.61 (p < 0.0001 for both), respectively. These results suggest gliptins should be prescribed with caution to patients with type 2 diabetes with coexisting Alzheimer’s and other dementias, or patients receiving long-term use of thiazides and loop diuretics. The use of sitagliptin over linagliptin and vildagliptin should be preferred in these patients.
Downloads
References
Joly P, Baricault S, Sparsa A, Bernard P, Bedane C, Duvert-Lehembre S, et al. Incidence and mortality of bullous pemphigoid in France. J Invest Dermatol 2012; 132: 1998-2004.
https://doi.org/10.1038/jid.2012.35 DOI: https://doi.org/10.1038/jid.2012.35
Schmidt E, Zillikens D. Pemphigoid diseases. Lancet 2013; 381: 320-332.
https://doi.org/10.1016/S0140-6736(12)61140-4 DOI: https://doi.org/10.1016/S0140-6736(12)61140-4
Clape A, Muller C, Gatouillat G, Le Jan S, Barbe C, Pham BN, et al. Mucosal involvement in bullous pemphigoid is mostly associated with disease severity and to absence of anti-BP230 autoantibody. Front Immunol 2018; 9: 479.
https://doi.org/10.3389/fimmu.2018.00479 DOI: https://doi.org/10.3389/fimmu.2018.00479
Kasperkiewicz M, Zillikens D. The pathophysiology of bullous pemphigoid. Clin Rev Allergy Immunol 2007; 33: 67-77.
https://doi.org/10.1007/s12016-007-0030-y DOI: https://doi.org/10.1007/s12016-007-0030-y
Muscelli E, Casolaro A, Gastaldelli A, Mari A, Seghieri G, Astiarraga B, et al. Mechanisms for the antihyperglycemic effect of sitagliptin in patients with type 2 diabetes. J Clin Endocrinol Metab 2012; 97: 2818-2826.
https://doi.org/10.1210/jc.2012-1205 DOI: https://doi.org/10.1210/jc.2012-1205
Kang SM, Park JH. Pleiotropic benefits of DPP-4 inhibitors beyond glycemic control. Clin Med Insights Endocrinol Diabetes 2021; 14: 11795514211051698.
https://doi.org/10.1177/11795514211051698 DOI: https://doi.org/10.1177/11795514211051698
Benzaquen M, Borradori L, Berbis P, Cazzaniga S, Valero R, Richard MA, et al. Dipeptidyl peptidase IV inhibitors, a risk factor for bullous pemphigoid: retrospective multicenter case-control study from France and Switzerland. J Am Acad Dermatol 2018; 78: 1090-1096.
https://doi.org/10.1016/j.jaad.2017.12.038 DOI: https://doi.org/10.1016/j.jaad.2017.12.038
Kawaguchi Y, Shimauchi R, Nishibori N, Kawashima K, Oshitani S, Fujiya A, et al. Dipeptidyl peptidase-4 inhibitors-associated bullous pemphigoid: a retrospective study of 168 pemphigoid and 9,304 diabetes mellitus patients. J Diabetes Investig 2019; 10: 392-398.
https://doi.org/10.1111/jdi.12877 DOI: https://doi.org/10.1111/jdi.12877
Kridin K, Bergman R. Association of bullous pemphigoid with dipeptidyl-peptidase 4 inhibitors in patients with diabetes: estimating the risk of the new agents and characterizing the patients. JAMA Dermatol 2018; 154: 1152-1158.
https://doi.org/10.1001/jamadermatol.2018.2352 DOI: https://doi.org/10.1001/jamadermatol.2018.2352
Lee SG, Lee HJ, Yoon MS, Kim DH. Association of dipeptidyl peptidase 4 inhibitor use with risk of bullous pemphigoid in patients with diabetes. JAMA Dermatol 2019; 155: 172-177.
https://doi.org/10.1001/jamadermatol.2018.4556 DOI: https://doi.org/10.1001/jamadermatol.2018.4556
Plaquevent M, Tetart F, Fardet L, Ingen-Housz-Oro S, Valeyrie-Allanore L, Bernard P, et al. Higher frequency of dipeptidyl peptidase-4 inhibitor intake in bullous pemphigoid patients than in the French general population. J Invest Dermatol 2019; 139: 835-841.
https://doi.org/10.1016/j.jid.2018.10.045 DOI: https://doi.org/10.1016/j.jid.2018.10.045
Varpuluoma O, Forsti AK, Jokelainen J, Turpeinen M, Timonen M, Huilaja L, et al. Vildagliptin significantly increases the risk of bullous pemphigoid: a Finnish nationwide registry study. J Invest Dermatol 2018; 138: 1659-1661.
https://doi.org/10.1016/j.jid.2018.01.027 DOI: https://doi.org/10.1016/j.jid.2018.01.027
Skandalis K, Spirova M, Gaitanis G, Tsartsarakis A, Bassukas ID. Drug-induced bullous pemphigoid in diabetes mellitus patients receiving dipeptidyl peptidase-IV inhibitors plus metformin. J Eur Acad Dermatol Venereol 2012; 26: 249-253.
https://doi.org/10.1111/j.1468-3083.2011.04062.x DOI: https://doi.org/10.1111/j.1468-3083.2011.04062.x
Kridin K, Cohen AD. Dipeptidyl-peptidase IV inhibitor-associated bullous pemphigoid: a systematic review and meta-analysis. J Am Acad Dermatol 2021; 85: 501-503.
https://doi.org/10.1016/j.jaad.2018.09.048 DOI: https://doi.org/10.1016/j.jaad.2018.09.048
Chen YJ, Wu CY, Lin MW, Chen TJ, Liao KK, Chen YC, et al. Comorbidity profiles among patients with bullous pemphigoid: a nationwide population-based study. Br J Dermatol 2011; 165: 593-599.
https://doi.org/10.1111/j.1365-2133.2011.10386.x DOI: https://doi.org/10.1111/j.1365-2133.2011.10386.x
Di Zenzo G, Della Torre R, Zambruno G, Borradori L. Bullous pemphigoid: from the clinic to the bench. Clin Dermatol 2012; 30: 3-16.
https://doi.org/10.1016/j.clindermatol.2011.03.005 DOI: https://doi.org/10.1016/j.clindermatol.2011.03.005
Forsti AK, Jokelainen J, Timonen M, Tasanen K. Risk of death in bullous pemphigoid: a retrospective database study in Finland. Acta Derm Venereol 2016; 96: 758-761.
Kershenovich R, Hodak E, Mimouni D. Diagnosis and classification of pemphigus and bullous pemphigoid. Autoimmun Rev 2014; 13: 477-481.
https://doi.org/10.1016/j.autrev.2014.01.011 DOI: https://doi.org/10.1016/j.autrev.2014.01.011
Huttelmaier J, Benoit S, Goebeler M. Comorbidity in bullous pemphigoid: up-date and clinical implications. Front Immunol 2023; 14: 1196999.
https://doi.org/10.3389/fimmu.2023.1196999 DOI: https://doi.org/10.3389/fimmu.2023.1196999
Stavropoulos PG, Soura E, Antoniou C. Drug-induced pemphigoid: a review of the literature. J Eur Acad Dermatol Venereol 2014; 28: 1133-1140.
https://doi.org/10.1111/jdv.12366 DOI: https://doi.org/10.1111/jdv.12366
Verheyden MJ, Bilgic A, Murrell DF. A systematic review of drug-induced pemphigoid. Acta Derm Venereol 2020; 100: adv00224.
https://doi.org/10.2340/00015555-3457 DOI: https://doi.org/10.2340/00015555-3457
Tasanen K, Varpuluoma O, Nishie W. Dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid. Front Immunol 2019; 10: 1238.
https://doi.org/10.3389/fimmu.2019.01238 DOI: https://doi.org/10.3389/fimmu.2019.01238
Kridin K, Ludwig RJ. The growing incidence of bullous pemphigoid: overview and potential explanations. Front Med (Lausanne) 2018; 5: 220.
https://doi.org/10.3389/fmed.2018.00220 DOI: https://doi.org/10.3389/fmed.2018.00220
Persson MSM, Harman KE, Vinogradova Y, Langan SM, Hippisley-Cox J, Thomas KS, Gran S. Incidence, prevalence and mortality of bullous pemphigoid in England 1998-2017: a population-based cohort study. Br J Dermatol 2021; 184: 68-77.
https://doi.org/10.1111/bjd.19022 DOI: https://doi.org/10.1111/bjd.19022
Leiter LA, Teoh H, Braunwald E, Mosenzon O, Cahn A, Kumar KM, et al. Efficacy and safety of saxagliptin in older participants in the SAVOR-TIMI 53 trial. Diabetes Care 2015; 38: 1145-1153.
https://doi.org/10.2337/dc14-2868 DOI: https://doi.org/10.2337/dc14-2868
Langan SM, Groves RW, West J. The relationship between neurological disease and bullous pemphigoid: a population-based case-control study. J Invest Dermatol 2011; 131: 631-636.
https://doi.org/10.1038/jid.2010.357 DOI: https://doi.org/10.1038/jid.2010.357
Li L, Chen J, Wang B, Yao Y, Zuo Y. Sera from patients with bullous pemphigoid (BP) associated with neurological diseases recognized BP antigen 1 in the skin and brain. Br J Dermatol 2009; 160: 1343-1345.
https://doi.org/10.1111/j.1365-2133.2009.09122.x DOI: https://doi.org/10.1111/j.1365-2133.2009.09122.x
Kridin K, Avni O, Damiani G, Tzur Bitan D, Onn E, Weinstein O, Cohen AD. Dipeptidyl-peptidase IV inhibitor (DPP4i) confers increased odds of bullous pemphigoid even years after drug initiation. Arch Dermatol Res 2023; 315: 33-39.
https://doi.org/10.1007/s00403-021-02317-9 DOI: https://doi.org/10.1007/s00403-021-02317-9
Gravani A, Christou P, Tigas S, Bassukas ID. Co-medications and dipeptidyl peptidase-4 inhibitors associated bullous pemphigoid. An Bras Dermatol 2021; 96: 782-784.
https://doi.org/10.1016/j.abd.2020.10.010 DOI: https://doi.org/10.1016/j.abd.2020.10.010
Jedlowski PM, Jedlowski MF, Fazel MT. DPP-4 inhibitors and increased reporting odds of bullous pemphigoid: a pharmacovigilance study of the FDA Adverse Event Reporting System (FAERS) from 2006 to 2020. Am J Clin Dermatol 2021; 22: 891-900.
https://doi.org/10.1007/s40257-021-00625-4 DOI: https://doi.org/10.1007/s40257-021-00625-4
Phan K, Charlton O, Smith SD. Dipeptidyl peptidase-4 inhibitors and bullous pemphigoid: a systematic review and adjusted meta-analysis. Australas J Dermatol 2020; 61: e15-e21.
https://doi.org/10.1111/ajd.13100 DOI: https://doi.org/10.1111/ajd.13100
Sun L, Wang C, Wu C, Zhou Y, Wang C. Analysis of the clinical characteristics of dipeptidyl peptidase-4 inhibitor-induced bullous pemphigoid. Ann Pharmacother 2022; 56: 205-212.
https://doi.org/10.1177/10600280211022722 DOI: https://doi.org/10.1177/10600280211022722
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2024 Dana Shalmon, Efrat Bar-Ilan, Alon Peled, Shamir Geller, Jonathan Bar, Naama Schwartz, Eli Sprecher, Mor Pavlovsky
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
